Absci (ABSI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Voting matters and shareholder proposals
Election of two Class II directors for a three-year term expiring at the 2029 annual meeting or until successors are elected and qualified.
Ratification of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Additional business may be transacted as properly brought before the meeting or any adjournment.
Board of directors and corporate governance
Board has nominated Prof Sir Menelas Pangalos, Ph.D., and Daniel Rabinovitsj for election as Class II directors.
Audit committee and external auditor matters
Proposal to ratify Ernst & Young LLP as the external auditor for the upcoming fiscal year.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Absci
- ABS-201 advances in AGA and endometriosis, with cash runway into 2028 and pipeline expansion.ABSI
Q1 20268 May 2026 - AI-driven platform accelerates antibody drug discovery, advancing ABS-201 for AGA and endometriosis.ABSI
Corporate presentation7 May 2026 - Annual meeting to elect directors, ratify auditor, and highlight clinical and AI platform progress.ABSI
Proxy filing23 Apr 2026 - ABS-201 targets AGA and endometriosis with AI-designed antibodies, aiming for major clinical milestones.ABSI
25th Annual Needham Virtual Healthcare Conference16 Apr 2026 - ABS-201 clinical progress and strong cash reserves support major milestones despite higher net loss.ABSI
Q4 202524 Mar 2026 - AI-driven pipeline targets AGA and endometriosis, with pivotal data and commercialization plans ahead.ABSI
Leerink Global Healthcare Conference 20269 Mar 2026 - ABS-201 leverages AI for hair regrowth, targeting a $25B+ market with rapid, durable results.ABSI
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - AI-driven drug discovery platform accelerates antibody design and clinical progress with a hybrid model.ABSI
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Q2 revenue fell 62% to $1.3M, net loss narrowed, and cash runway extends into 2027.ABSI
Q2 20241 Feb 2026